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An intronic G4C2 hexanucleotide repeat expansion in C9ORF72 is a major cause of amyotrophic lateral
sclerosis and frontotemporal lobar degeneration. Several mechanisms including RNA toxicity, repeat-
associated non-AUG translation mediated dipeptide protein aggregates, and haploinsufﬁciency of
C9orf72 have been implicated in the molecular pathogenesis of this disorder. The aims of this study were
to compare the use of two different Southern blot probes for detection of repeat expansions in an
amyotrophic lateral sclerosis and frontotemporal lobar degeneration pathological cohort and to deter-
mine the levels of C9orf72 transcript variants and protein isoforms in patients versus control subjects.
Our Southern blot studies identiﬁed smaller repeat expansions (250e1800 bp) that were only detectable
with the ﬂanking probe highlighting the potential for divergent results using different Southern blotting
protocols that could complicate genotypeephenotype correlation studies. Further, we characterize a new
C9orf72 antibody and show for the ﬁrst time decreased C9orf72 protein levels in the frontal cortex from
patients with a pathological hexanucleotide repeat expansion. These data suggest that a reduction in
C9orf72 protein may be a consequence of the disease.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
An intronic G4C2 hexanucleotide repeat expansion in the ﬁrst
intron or alternative promoter of the uncharacterized C9ORF72
gene was identiﬁed as the cause of amyotrophic lateral sclerosis
(ALS), frontotemporal lobar degeneration (FTLD), and ALS-FTLD
syndrome linked to chromosome 9p21 (DeJesus-Hernandez
et al., 2011; Gijselinck et al., 2012; Renton et al., 2011). Repeat-
primed polymerase chain reaction detection of hexanucleotide
expansions in a large cohort of ALS and FTLD cases identiﬁed
expansions in 8% of sporadic ALS, 39% of familial ALS, 7% sporadic
of FTLD, and 25% of familial FTLD cases (Majounie et al., 2012b).gical Medicine and Clinical
tics and Genomics, School of
aindy Road, Cathays, Cardiff,
)2920 687068.
r Inc. Open access under CC BY license.Expansions have also been reported in conﬁrmed cases of Alz-
heimer’s disease (Majounie et al., 2012a), corticobasal, and ataxic
syndromes (Lindquist et al., 2013; Snowden et al., 2012).
Although commonly used polymerase chain reaction (PCR)-based
methods allow the detection of repeat expansions, they are un-
able to size the expansions hampering further genotypeephe-
notype studies. Southern blot protocols allow the sizing of the
expansions, however only a limited number have been published
to date (Beck et al., 2013; Buchman et al., 2013; DeJesus-
Hernandez et al., 2011; van Blitterswijk et al., 2013). Studies
analyzing sufﬁcient samples numbers have reported a correlation
of modal repeat size with age at clinical onset of symptoms (Beck
et al., 2013; van Blitterswijk et al., 2013), however further cross-
sectional studies are required to strengthen these ﬁndings.
Preliminary studies suggest a complex pathological mecha-
nism associated with the C9ORF72 hexanucleotide repeat
expansion (Ash et al., 2013; DeJesus-Hernandez et al., 2011; Mori
et al., 2013b). A number of reports have shown decreased levels
of C9orf72 transcripts in expansion cases suggesting loss-of-
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et al., 2012; Mori et al., 2013b). However, the effect on protein
isoform levels has yet to be determined.
In this study we compared the use of repeat-derived and
single-copy repeat ﬂanking Southern blot probes for detection of
hexanucleotide expansions in an ALS-FTD pathological cohort.
Furthermore, we generated and characterized a custom anti-
C9orf72 polyclonal antibody to investigate C9orf72 protein
abundance in hexanucleotide repeat expansion carriers.
2. Methods
2.1. Subjects
Subjects were recruited as part of a study of familial ALS and
FTLD in Wales (REC for Wales 09/MRE09/35). Additional cases
were identiﬁed in the Oxford Brain Bank. (REC for England 07/
H0606/85). All cases showed ALS or FTLD neuropathology char-
acteristic of C9ORF72 mutation carriers, namely a combination
of TDP-43 positive and non-TDP-43 p62-positive inclusions.
Following consent, blood samples were obtained for DNA
extraction and the establishment of lymphoblastoid cell lines.
Tissue was obtained at postmortem for neuropathological
assessment and molecular pathological study. Patients had a
primary diagnosis of ALS (n ¼ 6), pure FTLD (n ¼ 1), and ALS-
FTLD (n ¼ 9). A family history of ALS and/or FTLD was present
in 11 cases. Three members came from the Gwent kindred in
whom the C9ORF72 expansion was previously identiﬁed (Renton
et al., 2011) (clinical information in Supplementary Table 1).
2.2. Southern blot
The C9ORF72 single-copy repeat ﬂanking probe sequence
(Southern blot restriction digests and probe location shown in
Supplementary Fig. 1) was PCR ampliﬁed (primers in
Supplementary Table 4) from control genomic DNA (gDNA) and
cloned into pGEM-T (Promega, Southampton, UK). Digoxigenin
(DIG)-labeled probewas ampliﬁed from puriﬁed plasmid using the
PCR DIG Probe Synthesis Kit (Roche Applied Science, Burgess Hill,
UK). The PCR product was puriﬁed using a gel extraction kit
(Qiagen, Manchester, UK) before use.
gDNA (5e7.5 mg) was digested overnight with EcoRI-HF
(40 U)/BamHI-HF (40 U) or only EcoRI (40 U). Next day, digests
were supplemented with 20 U additional enzyme(s) and incu-
bated for a further 2 hours. Southern blotting reagents were
purchased from Roche Applied Science unless otherwise stated.
Digested DNA was separated by electrophoresis on 0.8% agarose
gels and transferred onto positively charged nylon membranes by
capillary blotting (0.4 M NaOH) followed by baking at 80 C for 2
hours. Membranes were pre-hybridized with DIG Easy Hyb buffer
(3 hours at 46 C) before overnight hybridization at 46 C with
hybridization buffer containing 1 mL/mL C9ORF72 ﬂanking DIG-
probe. Membranes were washed in 2 saline sodium citrate
with 0.1% (wt/vol) sodium dodecyl sulfate (SDS) while the oven
was ramped from 46 C to 65 C. Two 15 minutes high stringency
washes were performed in 0.5  saline sodium citrate þ 0.1% (wt/
vol) SDS at 65 C. Detection of hybridized DIG-probe was carried
out using the DIG wash and block kit and CDP-Star reagent as a
chemiluminescent substrate. Signals were visualized on Kodak X-
OMAT LS ﬁlm after 1e4 hours. Estimation of repeat expansion
ranges were performed as described previously (Beck et al.,
2013). Southern blots using a DIG-labeled 5xGGGGCC probe
(hexanucleotide pentamer probe) were performed as previously
described with stringency washes and probe detection as
described previously (Beck et al., 2013).2.3. Reverse transcriptase-PCR and quantitative PCR
Two independent quantitative PCR (qPCR) experiments were
carried out. For the ﬁrst set, total RNA was extracted from tissue
samples using TRI Reagent (Ambion, Paisley, UK) and treated with
DNA-free DNase (Ambion) before quantiﬁcation and quality
assessment. RNA integrity (RIN) was checked on an Agilent 2100
Bioanalyzer with a RIN cutoff of 4 for use in qPCR. Cases and
control subjects had comparable RIN ranges. RNA was reverse
transcribed to complementary DNA (cDNA) using random deca-
mers and the Retroscript cDNA synthesis kit (Ambion). qPCR was
performed using Brilliant III ultra-fast SYBR Green PCR reagent
(Agilent Technologies, Wokingham, UK) following manufacturer’s
instructions and custom C9ORF72 primers (Supplementary
Table 3) and analyzed on an ABI 7900HT system (Applied Bio-
systems, Paisley, UK). Primer efﬁciencies were determined for
primer pairs by generation of a standard curve before use on
experimental samples. Three technical replicates were performed
for each sample. Relative quantiﬁcation was performed using the
DDCt method after normalization to ACTNB. Statistical signiﬁ-
cance of DCt values was determined using a 1-tailed t test
assuming unequal variance.
For the second set of experiments, RNA was extracted from
frozen brain tissue using the Qiagen RNeasy Lipid Tissue Mini Kit
with on-column DNAse treatment to remove genomic DNA. RNA
quality was then assessed as previously mentioned (RIN values
4.1e7.3 with no signiﬁcant difference between groups). cDNA was
generated from 3.5 mg RNA input using a SuperScript VILO cDNA
synthesis kit with random hexamer primers (Life Technologies,
Paisley, UK). RT-PCR was carried out with forward primers in
C9ORF72 exon 1a (GTCAAACAGCGACAAGTTCCG) and 1b (AGGCG-
CAGGCGGTGGCGAGTG) and reverse primer in exon 2
(ACCTGTTCTGTCTTTGGAGCC) using Sigma Taq polymerase in a
standard PCR reaction, annealing temperature 59 C, 30 cycles.
cDNA input for the exon 1 b PCRwas 50% of that for the exon 1a PCR.
PCR products were resolved on a 1.5% agarose gel stained using
GelRed. qPCR was carried out using a previously described custom
made TaqMan assay detecting the exon 1B containing variant 1
(NM_018325.3) (DeJesus-Hernandez et al., 2011) (Applied Bio-
systems). Reactionswere carried out in triplicate on a Rotor-GeneQ
cycler (Qiagen) using TaqManGeneExpressionMastermix (Applied
Biosystems). Data were analyzed using the DDCt method with
GAPDH (assay ID Hs00266705, Applied Biosystems) as a reference
gene. Ct values for GAPDH were evenly distributed across geno-
types and regions examined. DCt values were compared using an
unpaired t test not assuming equal variances.
2.4. Antibody production
The custom anti-C9orf72 rabbit polyclonal antibody (C9-3721)
was generated from an N-terminal thioredoxin fusion of C9orf72
short isoform (Thx-C9orf72-Short). Human C9orf72 short was
ampliﬁed from SH-SY5Y cDNA (primers in Supplementary
Table 4). The PCR product was digested and cloned into the
EcoRI/NotI sites of pET32b (Clontech, Mountain View, CA, USA).
Construct was sequence veriﬁed before use. Thx-C9orf72-Short
expression was induced in transformed BL21(DE3) Escherichia
coli (Agilent Technologies) using 1 mM isopropyl b-D-1-thio-
galactopyranoside (IPTG) for 3 hours at 37 C. Thx-C9orf72-Short
was puriﬁed using HisPur resin according to the manufacturer’s
instructions (Thermo Fisher Scientiﬁc, Loughborough, UK)
following solubilization in sonication buffer (20 mM Tris pH 8.0,
100 mM NaCl, 0.1% Triton X-100) using a Vibra-Cell Ultrasonic
Processor (Sonics & Materials Inc, Newtown, CT, USA). Puriﬁed
fusion protein was used as the antigen for custom rabbit
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Custom antisera were immunoafﬁnity puriﬁed against the anti-
gen following pre-absorption against thioredoxin and glial
ﬁbrillary acidic protein (Thx-GFAP expressed in BL21(DE3)
transformed with GFAP (pET32a)).2.5. Western blotting
Protein extracts were separated by SDS-PAGE and immuno-
blotted as previously described (Esapa et al., 2007). Primary an-
tibodies were incubated overnight at 4 C. C9orf72 commercial
antibodies were used at 1:100 dilutions, custom anti-C9orf72 C9-
3721 at 1:250, anti-c-myc 9E10 at 1:350 and anti-b-actin (Sigma-
Aldrich, Dorset, UK) at 1:2500. After washing the membranes
were incubated with IRDye 800 anti-mouse IgG (Rockland Im-
munochemicals, Gilbertsville, PA, USA) and Alexa Fluor 680 anti-
rabbit IgG (Life Technologies) secondary antibodies. Simultaneous
2-color detection was performed using an Odyssey infrared im-
aging system (LI-COR Biosciences UK Ltd, Cambridge, UK). For
quantiﬁcation samples were run in triplicate with the inclusion of
a recombinant C9orf72 protein blot standardizer. Membranes
were incubated with C9-3721 and anti-b-actin antibodies before
incubation with appropriate IRDye-conjugated secondary anti-
bodies. Speciﬁc quantiﬁcation of the approximate 48 kDa full
length C9orf72 isoform (indicated by arrowheads on the immu-
noblot images) was performed using the details view in Odyssey
application software with the average background method and
normalizing to endogenous b-actin signal. Blots were normalized
using the full-length recombinant C9orf72 standardizer (anno-
tated as myc-C9 LF in the ﬁgure panels) before collation of the
normalized signal intensity data. Statistical signiﬁcance of
normalized intensity values was determined using a 1-tailed t
test assuming unequal variance.Fig. 1. C9ORF72 repeat expansion analysis of frontal cortex and cerebellar postmortem
tissue using 2 Southern blot protocols. Genomic DNA extracted from frontal cortex (A)
and cerebellar cortex (B) were digested with AluI/DdeI and analyzed using the pub-
lished hexanucleotide Southern blot probe. Cerebellar cortex gDNA were also analyzed
with a novel ﬂanking Southern blot probe following EcoRI/BamHI restriction digest (C).
The ﬂanking probe allows detection of normal range alleles (white arrowhead) that
matched the genotypes determined by ﬂanking PCR (Supplementary Table 1). Analysis
of path cases (ALS1-15) with the hexanucleotide probe demonstrated the presence of
large repeat expansion products (>4000 bp) compared with controls (CON1-6). The
expansion products were weaker for ALS5, ALS7, and ALS14. NDO5077 (unaffected
control) and ALS15 LCL (expansion positive case) samples were used as internal con-
trols for Southern blots. Analysis of cerebellar tissue with the ﬂanking probe indicated
that ALS7 had a reduced modal repeat size of 3000e4200 bp (indicated by black
arrowhead). ALS5 had a weaker expansion signal compared with other samples. Ab-
breviations: PCR, polymerase chain reaction; LCL, lymphoblastoid cell line.3. Results
3.1. Comparative Southern blot detection of C9ORF72
hexanucleotide repeat expansions
Since the discovery of the C9ORF72 hexanucleotide repeat
expansion, most studies have used PCR based methods for the
detection of repeat expansions (DeJesus-Hernandez et al., 2011).
Initial genetic analysis of the pathological material also used
these methods (Supplementary Table 1) with all expansion pos-
itive cases showing a single detectable allele by ﬂanking PCR and
extended sawtooth repeat-primed PCR product of >30 peaks. A
limited number of studies have used Southern blotting for anal-
ysis of repeat expansion size using both repeat-derived and
single-copy repeat ﬂanking probes (Beck et al., 2013; Buchman
et al., 2013; DeJesus-Hernandez et al., 2011; van Blitterswijk
et al., 2013). For the purpose of estimating repeat size in our
pathological cohort we compared the use of a novel repeat
ﬂanking Southern probe (single copy probe) and a published
hexanucleotide probe (hexanucleotide pentamer probe).
The hexanucleotide probe showed increased sensitivity of
detection for large repeat expansions compared with the single-
copy probe, with overlap in signal representing modal repeat
sizes (Fig. 1). Cerebellar samples (Fig. 1B) consistently showed
reduced modal expansion sizes when compared with the frontal
cortex samples (Fig. 1A). Southern blot analysis of multiple brain
and peripheral tissue samples from a single affected individual
(ALS15) demonstrated a reduced modal expansion size range in
cerebellar tissue compared with other brain regions examined
(Supplementary Fig. 2). Peripheral tissues such as spleen, skeletalmuscle, and blood showed an extended repeat expansion size
range between that observed in frontal cortex and cerebellum.
Southern blot analysis of cerebellar tissue using both probes
(Fig. 1B and C) resulted in a similar pattern of expansion sizes
across most of the pathological samples. Regression analysis of
the approximate median repeat sizes from both Southern
methods showed evidence of linear correlation (R2 ¼ 0.89, F
signiﬁcance ¼ 1.5  104). ALS5 showed a weak hybridization
signal with the hexanucleotide probe that was not visible with
the ﬂanking single-copy probe. Conversely the hybridization
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the ﬂanking probe. In one case (ALS7) the ﬂanking probe detec-
ted a smaller expansion product of approximately 3000e4200 bp
(130e330 repeats) whereas, the hexanucleotide probe detected a
weak signal at the low-resolution area of the agarose gel. Scatter
plots of median repeat size versus age at onset (AAO) for both
Southern methods suggested a potential trend of increasing
repeat size with later AAO (Supplementary Fig. 2). The correlation
was more apparent using the hexanucleotide probe (R2 ¼ 0.82,
F signiﬁcance ¼ 1.9  103) however, for the single-copy probe
ALS7 and ALS14 deviated from this trend (R2 ¼ 0.49,
F signiﬁcance ¼ 0.16).
Southern blot analysis of a Gwent kindred gDNA panel
(Renton et al., 2011) using the ﬂanking probe identiﬁed an
approximate 2500 bp product (60 repeats) present in an lym-
phoblastoid cell line sample from an affected member (NDO6769)
that was absent in blood extracted gDNA (Fig. 2A, black arrow-
head) and undetectable with the hexanucleotide probe (Fig. 2B).
This is possibly because of the clonal selection of B-lymphocytes
during Epstein-Barr virus (EBV) transformation. These Southern
blotting studies suggest that a subset of cases may show discor-
dant results between different Southern blot protocols, which
may be a consequence of sensitivity of the probe, repeat size
detection range of the Southern protocol or source of the DNA.
3.2. Analysis of C9ORF72 transcript and protein levels in
hexanucleotide repeat expansion carriers
A number of studies have described a reduction in C9orf72
transcript expression as a consequence of the hexanucleotide
expansion using qPCR (Ciura et al., 2013; DeJesus-Hernandez et al.,
2011; Gijselinck et al., 2012; Mori et al., 2013b). The repeat
expansion may predominantly affect variants containing the
alternatively spliced exon 1b as its proximal promoter region is
predicted to contain the hexanucleotide repeat sequence
(DeJesus-Hernandez et al., 2011). We initially examined C9orf72Fig. 2. Detection of an LCL speciﬁc product in the Gwent kindred affected case NDO6769 (A
probe identiﬁes an approximate 60 repeat product in NDO6769 LCL gDNA (indicated with a
blood extracted gDNA. This product was undetectable with the hexanucleotide probe (B). Abb
cell line.transcript levels using a panel of qPCR assays designed to target all
variants (C9-ALL), long forms (C9-LONG; NM_0.18325.3,
NM_001256054.1), short form (C9-SHORT; NM_145005.5), and
exon 1b-containing variant 1 (C9-EX1B; NM_0.18325.3). Consis-
tent with previous ﬁndings we identiﬁed a trend of reduction in
C9orf72 transcript levels in large expansion carriers versus con-
trols in all qPCR assays (Fig. 3B), although the reduction was most
apparent in the exon 1b-containing variant. This was then
conﬁrmed across several brain regions in an independent set of
qPCR experiments using a TaqMan probe detecting the exon
1b-containing variant (Fig. 3C). Overall expression was highest in
the cerebellum, although variability was high, possibly reﬂecting
tissue-sampling bias. The degree of expression reduction observed
in frontal cortex for exon 1b-containing variants was similar in the
two qPCR methods. Expression was also signiﬁcantly reduced in
the cerebellum, and there was a trend toward reduced expression
in the hippocampus and spinal cord.
Given the presence of the hexanucleotide expansion in the 50
end of C9ORF72 between alternative exons 1a and 1b, we then
wanted to investigate whether altered exon usage or aberrant
splice products occur in expansion carriers. Semiquantitative RT-
PCR with exon-ﬂanking primers was used to investigate the ra-
tio between isoforms, brain regions, and genotypes (Fig. 3D). No
obvious differences in the isoform ratios, and no new 50 splice
variants were apparent using this method.
To complement the qPCR data we then determined C9orf72
protein levels in our pathological cohort. Characterization of a
panel of commercially available C9orf72 antibodies demonstrated
a lack of speciﬁcity and suitable reactivity for endogenous C9orf72
(Supplementary Fig. 4). Therefore we proceeded with the gener-
ation of custom C9orf72 rabbit polyclonal antibodies for immu-
noblotting studies in pathological material. Speciﬁcity of the
puriﬁed C9-3721 antisera was conﬁrmed using small interfering
RNA-mediated knockdown of endogenous C9orf72 in HEK293T
cells (Fig. 4A) and mass spectrometry analysis of endogenous
C9orf72 immunoafﬁnity puriﬁed from HEK293T cells and). Southern blot of Gwent kindred DNA panel using the DIG-labeled C9ORF72 ﬂanking
black arrowhead with normal range alleles marked with a white arrowhead) but not
reviations: CB, cerebellum; DIG, digoxigenin; gDNA, genomic DNA; LCL, lymphoblastoid
Fig. 3. Quantiﬁcation of C9ORF72 transcripts in different brain regions. (A) Reported genomic architecture of C9ORF72 with the location of SYBR green qPCR assays. (B) qPCR analysis
of frontal cortex samples (10 cases and 5 controls). Data points show linearized and scaled DCt values, error bars show standard deviation with mean expression values as horizontal
bars. Statistical signiﬁcance was determined using 1-tailed t tests assuming unequal variance. Cases show a trend of reduced expression across all samples and assays although this is
most apparent with exon 1b-containing variant (NM_018325.3). (C) qPCR for exon 1b containing variant 1 (NM_018325.3) shows signiﬁcantly reduced expression in frontal cortex
and cerebellum of expansion carriers (n ¼ 5) compared to expansion negative (n ¼ 8) control cases, as well as a trend toward reduced expression in hippocampus and spinal cord.
(D) RT-PCR with forward primers in exon 1a and 1b, respectively, and reverse primer in exon 2 for the detection of variants NM_001256054.1, NM_145005.5, and NM_018325.3 in all
examined regions. While NM_018325.3 appears to be more abundant overall, no qualitative difference in the splice variant ratio is apparent between genotypes. Abbreviations:
RT-PCR, reverse transcriptase polymerase chain reaction; qPCR, quantitative polymerase chain reaction.
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Supplementary Table 6). Initial immunoblotting of postmortem
material and mass spectrometry data identiﬁed antibody cross-
reaction with GFAP (Fig. 4B, arrowheads) as noted in a previous
study (Satoh et al., 2012). This was conﬁrmed by immunoblotting
of lysates from cells transfected with recombinant GFAP (Fig. 4C).
GFAP cross-reactivity was removed via pre-absorption of C9-3721
through a recombinant GFAP column (Fig. 4B and C). The immu-
noblotting studies consistently detected approximate 48 kDa and50 kDa proteins in both cell lines and postmortem brain tissue
(Fig. 4A and D, indicated by arrowheads). Small interfering RNA-
mediated knockdown of C9orf72 in cell lines suggested that the
48 kDa protein corresponded to the full-length isoform (long
form) and the 50 kDa protein may be an additional cross-reaction
product. Western blot of postmortem brain tissue detected
approximate 27 and 29 kDa proteins of lower abundance that may
represent the short isoform (Supplementary Fig. 5B, white ar-
rowheads), however, this was not observed in cell lines. The 48-
Fig. 4. Analysis of C9orf72 protein levels in postmortem tissue using the custom rabbit polyclonal antibody C9-3721. (A) Immunoblotting of HEK293T lysates detects approximate 48
kDa and 50 kDa endogenous protein species. Knockdown of C9orf72 using a panel of siRNA duplexes (siC91-4) leads reduction of the 48-kDa species (black arrowhead, endo C9).
b-actin was used a loading control. (B) Initial immunoblots of postmortem frontal cortex tissue detected variable lower molecular weight (white arrowhead) and approximate 48-
kDa protein species (black arrowhead) that obscured the endogenous C9orf72 bands. These suspected GFAP-related products were removed using the pre-absorption method. (C)
Immunoblot analysis of HEK293Ts transfected with increasing amounts of a GFAP cDNA construct. C9-3721 showed evidence of cross-reactivity with recombinant GFAP that is
removed following pre-absorption using a recombinant GFAP column. (D) Example immunoblots of protein extractions from frontal cortex (11 cases and 6 controls) and cerebellar
cortex (12 cases and 6 controls) with recombinant myc-tagged C9orf72 long form blot control (myc-C9 LF, black arrowheads) used for LI-COR quantiﬁcation. Endogenous C9orf72
long form migrates at approximately 48 kDa (endo C9, white arrowheads). (E) Quantiﬁcation of C9orf72 protein levels using b-actin as a normalizer for total protein. Cases show a
signiﬁcant reduction in the long form compared with controls in frontal cortex using a 1-tailed t test assuming unequal variance. This was not observed in cerebellar cortex samples.
Abbreviations: cDNA, complementary DNA; GFAP, glial ﬁbrillary acidic protein; siRNA, small interfering RNA.
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human dermal ﬁbroblasts lines and lymphoblastoid lines and the
27 kDa form was undetectable (data not shown). Quantitative
immunoblotting of the 48-kDa isoform in frontal cortex samplesanalyzed by qPCR identiﬁed a signiﬁcant reduction in C9orf72
protein in repeat expansion cases, although this was not observed
in a similar analysis of cerebellar cortex tissue (Fig. 4E). Regression
analysis of normalized protein and expression levels of C9orf72
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gested evidence of correlation (Supplementary Fig. 6) with an
average C9orf72 reduction of approximately 25% in qPCR and
immunoblotting studies in frontal cortex. Comparison of expan-
sion size by Southern blot and protein or transcript levels did not
indicate a correlation, however, the small number of samples with
Southern blot, qPCR and immunoblotting data restricted such an
analysis.4. Discussion
Here we compare the use of both single-copy and
hexanucleotide-based Southern blotting probes for the detection
of C9ORF72 repeat expansions. Two samples were shown to have
short expansion products that were undetectable using the
hexanucleotide probe. This highlights the requirement for
Southern blotting techniques that can simultaneously detect
both large and small repeat expansions independent of repeat
composition such as our method or others recently described
(Buchman et al., 2013; van Blitterswijk et al., 2013). Southern
blot data of gDNA from cell lines should also be interpreted with
caution. The observation of reduced modal expansion sizes in
cerebellum could reﬂect the purer sampling of neurons from the
granule cell layer, whereas other brain regions such as frontal
cortex may contain a greater admixture of nonneuronal cells
that may be still mitotic. Our qPCR studies identiﬁed a signiﬁ-
cant reduction in C9ORF72 expression in both cerebellum and
frontal cortex although the effect on other potential pathological
markers such as hexanucleotide repeat-containing RNA foci and
dipeptide repeat-containing aggregate pathology was not
determined.
Two recent Southern blotting studies have observed a corre-
lation of increasing AAO with larger hexanucleotide repeat size
(Beck et al., 2013; van Blitterswijk et al., 2013). Analysis within
our small cohort also showed a possible trend of increasing AAO
with repeat expansion size. This contrasts with a number of
noncoding repeat expansion disorders such as Huntington’s
disease-like 2, fragile X tremor ataxia syndrome, and myotonic
dystrophy type one that show evidence of an inverse correlation
between age of onset and repeat expansion length (Hamshere
et al., 1999; Margolis et al., 2004; Tassone et al., 2007).
Although most neurons are postmitotic, the positive AAO and/or
repeat length correlation may result from somatic mosaicism
where large repeats may expand with age complicating the
interpretation of Southern blotting data with relation to clinical
features. Such a mechanism has been proposed for the intronic
CCTG repeat expansion in ZNF9 in myotonic dystrophy type 2
where increasing repeat length correlates with age at time of
blood withdrawal (Liquori et al., 2001). As we used DNA that was
extracted from macroscopically dissected tissue we cannot
identify whether the differences arise in neurons or nonneuronal
cell populations.
Using complementary qPCR assays in independent experi-
ments, we show evidence of reduced C9orf72 transcript in
several brain regions, despite relatively high variability within
groups. This may reﬂect the inherent difﬁculty of macroscopically
dissecting anatomically identical frozen samples for RNA analysis.
The reduction of C9ORF72 expression was most pronounced for
the exon 1b-containing variant. This may reﬂect a speciﬁc effect
of the hexanucleotide repeat expansion on the promotor region
of this variant. Little is known about the signiﬁcance of the two
exon 1a-containing variants, but our semi-quantitative RT-PCR
data suggest they are relatively less abundant than isoform 1.
Within the sensitivity of our assay, no change in the overallsplicing pattern between isoforms was apparent in the presence
of the expansion.
One of the key aspects of our study was to quantify C9orf72
transcript and protein levels in postmortem pathological material.
To achieve this, we generated and validated a custom C9orf72
antibody and applied it in quantitative immunoblots. We observed
a reduction in C9orf72 protein levels in frontal cortex but not
cerebellar cortex tissue of cases. However, a signiﬁcant reduction
in exon 1b-containing variants was detected in both tissues by
qPCR. Reduced expression of C9ORF72 has been identiﬁed in
postmortem brain tissue, lymphoblastoid cell lines, and neurons
differentiated from induced pluripotent stem cell (iPSC) lines
(Almeida et al., 2013; Ciura et al., 2013; DeJesus-Hernandez et al.,
2011; Gijselinck et al., 2012; Mori et al., 2013b). This could be
mediated primarily by hypermethylation of a proximal CpG island
(Xi et al., 2013) and interaction of the expanded hexanucleotide
repeat with trimethylated histones (Belzil et al., 2013). A study
using antisense morpholino-mediated knockdown of the Zebra-
ﬁsh C9ORF72 ortholog resulted in behavioral and cellular deﬁcits
including reduced motility and reduced axon length (Ciura et al.,
2013). However, recent studies using antisense oligonucleotide
mediated depletion of C9orf72 transcripts in iPSC derived neurons
and the mouse central nervous system did not observe any
adverse effects (Donnelly et al., 2013; Lagier-Tourenne et al., 2013;
Sareen et al., 2013). Furthermore, the description of a case ho-
mozygous for the C9ORF72 hexanucleotide repeat expansion that
falls within the usual disease spectrum argues against a loss-of-
function mechanism (Fratta et al., 2013). The identiﬁcation of
reduced C9ORF72 expression in ALS and FTLD cases with normal
repeat ranges (Ciura et al., 2013) implies that a reduction in
C9orf72 levels may also be a common pathogenic factor in ALS or
may be a consequence of the disease process.
Although its function is currently unknown bioinformatics
studies have identiﬁed C9orf72 as a putative member of the
DENN domain containing protein family that are known to
function as guanine nucleotide exchange factors for Rab GTPases
(Levine et al., 2013; Zhang et al., 2012). Existing protein interac-
tion data indicate that C9orf72 may be a component of protein
complexes involved in autophagosome initiation (Behrends et al.,
2010). Furthermore, a recent study found that neurons differen-
tiated from iPSC cells of C9ORF72 expansion carriers showed
increased sensitivity to chemical inhibitors of endosomal-
lysosomal and autophagy pathways compared with controls
(Almeida et al., 2013). Dysfunction of vesicular trafﬁcking pro-
cesses such as endosomal-lysosomal trafﬁcking and autophagy
may be a pathological consequence of the C9ORF72 hexanucleo-
tide repeat and has been implicated in other genetic forms of
motor neuron degeneration and FTD (Devon et al., 2006;
Filimonenko et al., 2007; Ju et al., 2009; Tumbarello et al.,
2013; Wild et al., 2011). A collection of studies analyzing neu-
rons differentiated from iPSCs derived from pathological expan-
sion carriers point toward a gain-of-function mechanism
resulting from toxic repeat-containing RNA inclusions and
insoluble peptide aggregates generated by non-AUG mediated
translation of the hexanucleotide repeat (Almeida et al., 2013;
Ash et al., 2013; DeJesus-Hernandez et al., 2011; Donnelly et al.,
2013; Lagier-Tourenne et al., 2013; Mori et al., 2013a, 2013b;
Sareen et al., 2013). These potentially neurotoxic molecules are a
result of bidirectional transcription of the expanded repeat
(Gendron et al., 2013; Lagier-Tourenne et al., 2013; Mizielinska
et al., 2013; Zu et al., 2013). Disentangling the contribution of
these pathological mechanisms awaits the generation of a range
of animal and cellular models. The production of a number of
sensitive and speciﬁc C9orf72 antibodies will also aid in the
investigation of such disease models.
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